Phase 2/3Completed
Randomized, Double-blind, Placebo-controlled Trial to Investigate Safety and Efficacy of Cerebrolysin™ in Patients With Aneurysmal Subarachnoid Hemorrhage (CESAR)
Randomized, Double-blind, Placebo-controlled Pilot Trial to Investigate Safety and Efficacy of Cerebrolysin™ in Patients With Aneurysmal Subarachnoid Hemorrhage
- Sponsor
- Kwong Wah Hospital (Academic or other)
- Enrollment
- 50 enrolled
- Conditions
- Subarachnoid Hemorrhage; Intracranial Aneurysm; Delayed Cerebral Ischemia; Delayed Ischemic Neurological Deficit
- Interventions
- Intravenous Cerebrolysin; Normal Saline
- Ages
- adults, older adults
- Registry
- NCT01787123
Full record on ClinicalTrials.gov
From the registry
This is a randomized, placebo-controlled, single-center clinical trial investigating the effectiveness of administrating intravenous Cerebrolysin™ (EVER NEURO Pharma, Austria), a preparation of low-molecular weight neurotrophic peptides and free amino acids, in improving the functional outcome of patients suffering from aneurysmal subarachnoid haemorrhage ( SAH). Cerebrolysin™ is a porcine-derived intravenous formulation composed of multiple lipid-soluble active agents that can cross the blood-brain barrier. It is a registered medication in several countries indicated for stroke and Alzheimer's disease. It contains several low molecular weight neuropeptides and free amino acids that possess neuroprotective and neurotrophic properties. It has been proven to arrest or mitigate several crucial steps along the ischemic cascade in preclinical studies. Cerebrolysin™ has been extensively investigated in patients suffering from Alzheimer's disease, brain trauma and ischemic stroke with promising clinical results. It's use in SAH patients has never been investigated and it is believed that…
Primary outcomes
- Global functional performance
History
Last registry update
Primary completion
Started
Registered